Neurology Medical News about Lymphoma Lymphoma, Large B-Cell, Diffuse

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
Annals of Oncology, 10/30/09

Villa D et al. – The addition of rituximab to CHOP (R–CHOP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improves outcome in patients with diffuse large B–cell lymphoma (DLBCL). The authors evaluated the risk of central nervous system (CNS) relapse in the R–CHOP in a population–based cohort of patients with DLBCL. The use of R–CHOP appears to reduce the overall risk of CNS relapse in patients with DLBCL particularly in patients who achieve a complete response.

<< Previous
Seasonality as a risk factor for sudden unexpected death in...

Next >>
Utility of levetiracetam in patients with subarachnoid hemorrhage

Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach
Hematological Oncology, 10/27/09 Relevance Score: 95%

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy
Annals of Oncology, 11/16/09 Relevance Score: 94%

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
Leukemia and Lymphoma, 11/04/09 Relevance Score: 94%

High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma
Leukemia and Lymphoma, 10/30/09 Relevance Score: 94%

Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
Journal of Clinical Oncology, 10/02/09 Relevance Score: 94%